论文部分内容阅读
目前国内开发、生产药物缓释微丸的空白最近被中法合资高新技术企业——上海爱的发制药有限公司填补。经国家药品监督管理局批准,该公司获得了中国制药史上的第一件缓释微丸的生产批文,这标志着中国制药工业技术进入了一个新的时代,我国制剂技术落后,缓释、控释品种稀少的局面将得到改观。这是日前在上海举行的“微丸技术在中国”研讨会上传出的信息。 缓释、控释微丸是国际上迅速发展的一种新剂型,它以血药浓度平稳、毒副反应小、服用次数少、可以和流质一起服用、价格相对低廉等特点深受广大医生及
At present, the gap in the development and production of drug sustained-release pellets in China has recently been filled by Sino-French high-tech joint venture-Shanghai Aifa Pharmaceutical Co., Ltd. Approved by the State Drug Administration, the company obtained the production approval of the first sustained-release pellet in the history of China’s pharmaceutical industry. This indicates that the pharmaceutical industry in China has entered a new era in which its technology is backward, controlled and controlled Sparse release of species will be changed. This is the message from the seminar “Pellets Technology in China” recently held in Shanghai. Sustained release and controlled release pellets are a new form of rapid development in the world. They are characterized by stable blood concentration, small toxic and side reactions, less taking time, relatively low liquidity,